Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead

Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients

Gilead Sciences Inc (NASDAQ: GILD)

Hookipa Pharma Stock Surges On HIV Pact With Gilead

Hookipa Pharma Stock Surges On HIV Pact With Gilead

Hookipa Pharma Inc (NASDAQ: HOOK)

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa

Here's a roundup of top developments in the biotech space over the last 24 hours.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

Gilead Sciences Inc (NASDAQ: GILD)

Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron

Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD).

GSK claims $1.2bn victory in HIV patent battle with US rival Gilead

Drugmaker GlaxoSmithKline today claimed a landmark victory in its competitive battle to dominate HIV treatment as a US rival agreed to hand over $1.25 billion to end a high-stakes global patent dispute.

Evening Standard

inkl

Read news from The Economist, FT, and more,
with one subscription

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates

Gilead Sciences Inc (NASDAQ: GILD) posted

Gilead Stock Dives After Two Major Charges Dig Into Fourth-Quarter Earnings

Gilead Stock Dives After Two Major Charges Dig Into Fourth-Quarter Earnings

Gilead Sciences reported lighter-than-expected fourth-quarter earnings late Tuesday, leading GILD stock to tumble in after-hours action.

Investors Business Daily

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings

FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings

Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way

Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way

Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.

Investors Business Daily

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years.

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to

Get all your
news in one place.

100’s of premium titles.
One news app.

Organisations

Gilead Sciences Inc

Gilead Sciences

GlaxoSmithKline

Sierra Oncology

ViiV Healthcare

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

255,498 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play